This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation

This study is ongoing, but not recruiting participants.
Brigham and Women's Hospital
Information provided by (Responsible Party):
Andrea K. Ng, MD, Dana-Farber Cancer Institute Identifier:
First received: September 9, 2005
Last updated: March 9, 2016
Last verified: March 2016
The main purpose of this study is to determine if it is possible to put into practice a cardiac screening program for survivors of Hodgkin's disease. In this study, we would also like to screen for cardiac risk factors that can be modified either through life-style changes or medications, to uncover significant abnormal heart findings in which treatments may be needed, and to see if there is a link between cardiac health and quality of life.

Condition Intervention
Hodgkin's Disease Procedure: Echo/Stress Echo

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation

Resource links provided by NLM:

Further study details as provided by Andrea K. Ng, MD, Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To determine the feasibility of a cardiac screening program in patients who are 5 to 10 years our from initial mediastinal irradiation for Hodgkin's disease. [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • To prospectively collect data on the prevalence of modifiable cardiac risk factors and the spectrum of cardiac structural abnormalities in this patient populations [ Time Frame: 3 years ]
  • to correlate cardiac structural abnormalities with quality of life and level of fatigue. [ Time Frame: 3 years ]

Enrollment: 210
Study Start Date: February 2004
Estimated Study Completion Date: April 2016
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cardiac screening

Participants will

  • meet with study cardiologist
  • undergo cardiac risk factors screening
  • undergo resting and stress echocardiogram
Procedure: Echo/Stress Echo
Participants will under resting echocardiogram and stress echocardiogram and the results will be interpreted by a cardiologist

Detailed Description:
  • On the day of the patient's scheduled follow-up visit with their oncologist, additional blood work will be obtained and the patient will fill out questionnaires concerning their general health and assessing quality of life.
  • A separate cardiology visit with a preventative cardiologist will be performed. At this visit, the patient will undergo a Stress Echocardiogram.
  • A Stress Echocardiogram is made up of three parts: Resting echo study, stress test and repeat echo while the heart is still beating fast.
  • A resting echo provides the baseline examination and demonstrates the size and function of various chambers of the heart.
  • The stress test involves exercise using a treadmill or a stationary bike. In patients who are unable to complete a high level of exercise due to physical limitations, stress to the heart is provided by a pharmaceutical or chemical stimulation to the heart. Exercise is started at a slower, warm-up speed and then increased every 3 minutes. Exercise is abruptly stopped once the patient exceeds 85% of the target rate. EKG recordings are made every minute of exercise and then again after exercise is stopped. Blood pressure is recorded at three minute intervals during exercise and then again at rest.
  • Immediately after exercise is stopped, the patient will undergo a repeat echocardiogram.
  • If no cardiac abnormalities are detected, the screening tests will be repeated every 3 years, if the patient is less than 10 years out from their initial treatment. If the patient is more than 10 years from initial treatment, then the tests will be repeated at approximately 18 months from the initial screening and once more at the end of the third year.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients treated at Brigham and Women's Hospital or Dana-Farber Cancer Institute for Hodgkin's disease with mediastinal irradiation
  • Age > or = to 15 years of age
  • Five years or longer after initial treatment
  • Relapse-free interval of > 1 year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00165425

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Principal Investigator: Peter Mauch, MD Dana-Farber Cancer Institute
  More Information

Responsible Party: Andrea K. Ng, MD, Associate Professor of Radiation Oncology, Dana-Farber Cancer Institute Identifier: NCT00165425     History of Changes
Other Study ID Numbers: 03-295
Study First Received: September 9, 2005
Last Updated: March 9, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Andrea K. Ng, MD, Dana-Farber Cancer Institute:
Cardiac screening
Cardiac stress test

Additional relevant MeSH terms:
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on July 21, 2017